Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07384975 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

A Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Navigator Medicines.

Recruiting
Registry status
Phase 2
Development phase
150
Enrollment target
10
Study locations

NCT07384975 is a Phase 2 study of Hidradenitis Suppurativa (HS) that is actively recruiting participants, run by Navigator Medicines. The registered enrollment target is 150 participants, below the 168-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (11% lower). The trial reports 10 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07384975, a Phase 2 study of Hidradenitis Suppurativa (HS), is actively recruiting participants, sponsored by Navigator Medicines.

RECRUITING
Registry status
Phase 2
Development phase
150 participants
Enrollment target
10
Study locations

Study Summary

The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS. The main endpoint of this study is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 16, meaning at least a 75% reduction in inflamed skin bumps (abscess and inflammatory nodule (AN) count) with no increase in number of abscesses or draining tunnels (channels under the skin that leak fluid or pus) compared to the baseline (start of the study). Participants will: * Receive NAV-240 dose 1, NAV-240 dose 2 or placebo as a drip into the veins (intravenous infusion). * Visit the clinic up to 9 times for checkups and tests over 22 weeks. * Complete a daily diary about their skin pain.

Conditions Studied

Hidradenitis Suppurativa (HS)

Interventions

  • DRUG NAV-240
  • DRUG Placebo to match NAV-240

Study Locations (10)

Florida

  • Accel Research Sites Network - Maitland
  • Floridian Research Institute - Miami
  • Cordova Research Institute - Miami
  • Tory Sullivan MD PA - Dermatology - North Miami Beach
  • MplusM - D&H Tamarac Research Center - Tamarac
  • ForCare Clinical Research - Tampa

Arizona

  • Medical Dermatology Specialist - Phoenix

Kentucky

  • Kentucky Advanced Medical Research LLC - Murray

New Hampshire

  • ActivMed Practices & Research, LLC - Portsmouth

New York

  • Equity Medical, LLC - The Bronx

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2026-01-05
Est. Completion 2027-10
Phase Phase 2

Sponsor

Navigator Medicines

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07384975

The ClinicalTrials.gov registry entry for NCT07384975 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 168-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (11% lower). The listed sponsor is Navigator Medicines, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 2 interventions - of which NAV-240 is the first listed.

NCT07384975 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Florida, Arizona, Kentucky.

Frequently Asked Questions

What is clinical trial NCT07384975 about?

NCT07384975 is a clinical study titled "A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa". The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS. The main endpoint of this study is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 1...

What is the current status of trial NCT07384975?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2026-01-05. Estimated completion is 2027-10.

What conditions does trial NCT07384975 study?

This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).

What interventions are being tested in trial NCT07384975?

The interventions under investigation include: NAV-240 (DRUG), Placebo to match NAV-240 (DRUG).

Who is sponsoring clinical trial NCT07384975?

This trial is sponsored by Navigator Medicines, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07384975 being conducted?

This trial has 10 study locations across Arizona, Florida, Kentucky, New Hampshire, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hidradenitis Suppurativa (HS)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hidradenitis Suppurativa (HS)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.